Drug intelligence / Profile preview

IRL201805

Development stage: Unknown
Lead developer: Revolo Biotherapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

IRL201805 is a first-in-class biologic drug being developed by Revolo Biotherapeutics (formerly Immune Regulation Ltd). It is a modified analogue of the endogenous immuno-regulatory protein, chaperonin binding immunoglobulin protein (BiP). It is primarily being developed for rheumatoid arthritis, having shown promising results in clinical trials with long-lasting immunomodulatory effects after a single intravenous dose.

Other names: Modified BiP

Targets

HSPA5 (Heat shock protein family A member 5)

Beyond the preview

Go deeper on IRL201805.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRL201805.

Explore the full profile